IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(11):2460-2467

Original Article
ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line
H1299

Kui Li, Zhi-Chuan Zhu, Yong-Jie Liu, Ji-Wei Liu, Hong-Tao Wang, Zhi-Qi Xiong, Xu Shen, Ze-Lan Hu, Jing Zheng

Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road,
Shanghai, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Received August 15, 2013; Accepted September 7, 2013; Epub September 15, 2013; Published October 1, 2013

Abstract: ZFX (zinc finger transcription factor, X chromosome-linked) contributes to the maintenance of different types of stem cells and the
progression of various cancers. We have previously reported that ZFX knockdown inhibits proliferation of glioma in vitro and in vivo. Since
overexpression of ZFX in lung cancer tissue correlates with lymph node metastasis, we hypothesized that ZFX may play a role in lung cancer. In
this study, we identified ZFX as a promoter of lung cancer growth and migration in a NSCLC (non-small cell lung carcinoma) cell line H1299.
ZFX knockdown caused proliferation inhibition determined by MTT assay and colony formation assay, G0/G1 arrest of cell cycle and slightly
increased proportion of apoptotic cells assessed by flow cytometry assay, decreased population of migrating cells showed by wound-healing
assay, increased cell senescence evidenced by senescence-associated β-galactosidase staining. ZFX knockdown also led to decreased
proportion of tumor bearing mice and reduced mean tumor volume in a subcutaneous tumor model. In addition, western blot showed that ZFX
knockdown down regulated a set of proteins involved in proliferation, survival and motility. Altogether, these results suggest that ZFX may be a
potential therapeutic target for NSCLC. (IJCEP1308040).

Keywords: ZFX, non-small cell lung carcinoma, growth, migration, senescence

Address correspondence to: Dr. Jing Zheng or Dr. Ze-Lan Hu, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China
University of Science and Technology, 130 Meilong Road, Shanghai, China. Tel: 0086-21-64250608; Fax: 0086-21-64250608; E-mail:
Zhengjing@ecust.edu.cn (Jing Zheng); Huzelan@hotmail.com (Ze-Lan Hu)